<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03926026</url>
  </required_header>
  <id_info>
    <org_study_id>NCX-4251-01</org_study_id>
    <nct_id>NCT03926026</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Dose-Escalation, Phase 2 Study Evaluating the Safety and Tolerability of NCX 4251 (Fluticasone Propionate Nanocrystal) Ophthalmic Suspension, 0.1% QD and BID for the Treatment of Acute Exacerbations of Blepharitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicox Ophthalmics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nicox Ophthalmics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-masked, placebo-controlled, Phase 2 study
      evaluating the safety and tolerability of NCX 4251 (fluticasone propionate nanocrystal)
      Ophthalmic Suspension 0.1% QD and BID for the treatment of acute exacerbations of
      blepharitis. The study will be performed in two sequential dose escalating cohorts.

      The study is designed to select the dose(s) of NCX 4251 to advance into the next stage of
      development, and to assess the safety and tolerability of NCX 4251 Ophthalmic Suspension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 18, 2019</start_date>
  <completion_date type="Actual">October 21, 2019</completion_date>
  <primary_completion_date type="Actual">October 21, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>sequential dose-escalating cohorts -- Cohort 1 (2 parallel groups) and Cohort 2 (2 parallel groups)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double-masked</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent ocular and systemic adverse events (safety and tolerability)</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of treatment-emergent ocular and systemic adverse events (safety and tolerability)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Blepharitis</condition>
  <arm_group>
    <arm_group_label>NCX 4251 QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NCX 4251 Ophthalmic Suspension, 0.1% once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo QD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NCX 4251 BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NCX 4251 Ophthalmic Suspension, 0.1% twice daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo twice daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone Propionate</intervention_name>
    <description>NCX 4251 Ophthalmic Suspension, 0.1%</description>
    <arm_group_label>NCX 4251 BID</arm_group_label>
    <arm_group_label>NCX 4251 QD</arm_group_label>
    <other_name>NCX 4251</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>NCX 4251 Ophthalmic Suspension, 0%</description>
    <arm_group_label>Placebo BID</arm_group_label>
    <arm_group_label>Placebo QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  history of blepharitis and meet qualifying criteria for an acute exacerbation of
             blepharitis in both eyes at Screening and Baseline/Day 1 Visits

          -  have a qualifying best-corrected visual acuity

        Exclusion Criteria:

          -  abnormality of the eyelids or lashes (other than blepharitis), or previous eyelid
             surgery

          -  IOP &gt; 21 mmHg at Screening or Baseline/Day 1 Visits

          -  use of steroids in the past 30 days or retinoids in the past 12 months

          -  uncontrolled systemic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomas Navratil, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nicox Ophthalmics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texan Eye</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 19, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2019</study_first_posted>
  <last_update_submitted>January 10, 2020</last_update_submitted>
  <last_update_submitted_qc>January 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blepharitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

